Alzheimer’s Drug Discovery Foundation: Drug Development RFP

If you are interested in this opportunity, please contact Carole King at carole.king@med.usc.edu.

• LOI due September 15, 2025
• Amount up to $5,000,000 (no indirects)
• Project duration is not specified (multi-year)

Supports investigational new drug (IND)-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices.

Novel, repurposed and repositioned drugs will be considered.

Therapeutic modalities of interest include small molecules, peptides, antibodies, gene therapies, antisense oligonucleotides, and stem cells.

Note that funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones.  Terms of agreements vary.